{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:59Z","timestamp":1786119419773,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/coc.0b013e3181d31ed2","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T05:24:09Z","timestamp":1269667449000},"page":"125-129","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Outcomes of Sorafenib Treatment in Patients With Metastatic Hepatocellular Carcinoma Who Had Been Previously Treated With Fluoropyrimidine Plus Platinum-based Chemotherapy"],"prefix":"10.1097","volume":"34","author":[{"given":"Ji-Won","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae-Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-You","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210128","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","article-title":"Global cancer statistics in the year 2000.","volume":"2","author":"Parkin","year":"2001","journal-title":"Lancet Oncol"},{"key":"R2-4-20210128","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"R3-4-20210128","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"R4-4-20210128","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jama.299.14.1669","article-title":"Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.","volume":"299","author":"Cheng","year":"2008","journal-title":"JAMA"},{"key":"R5-4-20210128","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma.","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"R6-4-20210128","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L","article-title":"Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial.","volume":"62","author":"Lai","year":"1988","journal-title":"Cancer"},{"key":"R7-4-20210128","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1046\/j.1440-1746.2001.02352.x","article-title":"Improved survival with oral administration of enteric-coated tegafur\/uracil for advanced stage IV-A hepatocellular carcinoma.","volume":"16","author":"Ishikawa","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R8-4-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/cncr.20841","article-title":"A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.","volume":"103","author":"Ikeda","year":"2005","journal-title":"Cancer"},{"key":"R9-4-20210128","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/hep.510270409","article-title":"Activation of mitogen-activated protein kinases\/extracellular signal-regulated kinases in human hepatocellular carcinoma.","volume":"27","author":"Ito","year":"1998","journal-title":"Hepatology"},{"key":"R10-4-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-230X-3-19","article-title":"Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis.","volume":"3","author":"Huynh","year":"2003","journal-title":"BMC Gastroenterol"},{"key":"R11-4-20210128","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1053\/j.gastro.2006.01.006","article-title":"Ubiquitous activation of Ras and Jak\/Stat pathways in human HCC.","volume":"130","author":"Calvisi","year":"2006","journal-title":"Gastroenterology"},{"key":"R12-4-20210128","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jhep.2004.09.006","article-title":"Angiogenesis and hepatocellular carcinoma.","volume":"41","author":"Semela","year":"2004","journal-title":"J Hepatol"},{"key":"R13-4-20210128","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"R14-4-20210128","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5.","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"R15-4-20210128","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma.","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"R16-4-20210128","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R17-4-20210128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"R18-4-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R19-4-20210128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2407-6-3","article-title":"Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.","volume":"6","author":"Park","year":"2006","journal-title":"BMC Cancer"},{"key":"R20-4-20210128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jjco\/hyn087","article-title":"Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.","volume":"38","author":"Ikeda","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"R21-4-20210128","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","article-title":"Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"R22-4-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cncr.24029","article-title":"Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.","volume":"115","author":"Yau","year":"2009","journal-title":"Cancer"},{"key":"R23-4-20210128","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/1097-0142(19891015)64:8<1700::AID-CNCR2820640824>3.0.CO;2-Z","article-title":"Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels: analysis of 606 patients.","volume":"64","author":"Nomura","year":"1989","journal-title":"Cancer"},{"key":"R24-4-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-8278(99)80173-1","article-title":"A new prognostic classification for predicting survival in patients with hepatocellular carcinoma: groupe d'etude et de traitement du carcinome hepatocellulaire.","volume":"31","author":"Chevret","year":"1999","journal-title":"J Hepatol"},{"key":"R25-4-20210128","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2008.18.8151","article-title":"New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.","volume":"27","author":"Chan","year":"2009","journal-title":"J Clin Oncol"},{"key":"R26-4-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1440-1746.2009.05784.x","article-title":"Hepatocellular carcinoma in the Asia pacific region.","volume":"24","author":"Yuen","year":"2009","journal-title":"J Gastroenterol Hepatol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201104000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:15:24Z","timestamp":1786040124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201104000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181d31ed2","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}